TKL will collaborate with the Myhrvold Lab (Princeton University) to develop CRISPR-based assays to rapidly detect multiple drug resistance mutations in Plasmodium falciparum and Mycobacterium tuberculosis for malaria and tuberculosis (TB) surveillance, respectively.
